Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.07 USD | +7.00% | +11.92% | -25.69% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.69% | 151M | |
+13.15% | 118B | |
+12.77% | 106B | |
-3.97% | 24.28B | |
+1.19% | 21.96B | |
-9.30% | 18.16B | |
-42.12% | 16.37B | |
-17.23% | 15.56B | |
+4.78% | 13.63B | |
+32.27% | 12.27B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Transcript : Seres Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022